Zymeworks Inc. announced on September 18, 2024, that it will present results from recent preclinical research for its antibody-drug conjugate (ADC) candidates, ZW220 and ZW251. These presentations are scheduled for the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference, taking place from October 23-25, 2024, in Barcelona.
The preclinical data will highlight the activity of ZW220 in models of non-small cell lung, ovarian, and uterine cancers. Additionally, ZW251's activity in hepatocellular carcinoma models will be showcased. Both candidates leverage Zymeworks' novel proprietary payload, ZD06519, indicating the company's continued advancement of its next-generation ADC programs.
This announcement signals ongoing progress in Zymeworks' wholly-owned pipeline, following the recent initiation of Phase 1 studies for ZW171 and ZW191. The company expects these ADC programs, ZW220 and ZW251, to remain on track for Investigational New Drug (IND) filings in 2025, demonstrating a consistent pace of development for its therapeutic candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.